Latest Breaking News On - Joshua brumm - Page 3 : comparemela.com

Dyne Therapeutics To Present At 42Nd Annual J.P. Morgan Healthcare Conference

Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE™ Platform in Developing Therapeutics for Rare Muscle Diseases

- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose-Dependent Splicing Correction, Muscle Delivery and DMPK Knockdown - - All Evaluable Patients in the 3.4 mg/kg Cohort Treated with DYNE-101.

Form 8-K Dyne Therapeutics, Inc. For: Jan 03

Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients ...

- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose-Dependent Splicing Correction, Muscle Delivery and DMPK Knockdown -

Dyne Therapeutics' Duchenne muscular dystrophy treatment shows promise

Dyne released promising new data on its Duchenne muscular dystrophy drug, DYNE-251, as well as its myotonic dystrophy type 1 treatment DYNE-101.